Galectin (GALT) Investors Take Profit Following Pop on GR-MD-02 Patent News Monday

July 24, 2012 10:08 AM EDT Send to a Friend
Galectin Therapeutics (Nasdaq: GALT) shares are pulling back Tuesday, following a strong 63.8 percent move higher Monday on the back of positive carbohydrate-based galectin inhibitor compound news.

Galectin ripped following reports it was issued U.S. Patent and Trademark Office for Patent Number 8,236,780 “Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies."

Shares are down over 8 percent in early trading.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Insiders' Blog, Momentum Movers

Add Your Comment